



Payment Policy: COVID-19 Billing Guidelines

(Commercial/Medicare Advantage)

Last Review Date: 3/10/2021

Number: RE.MM.101

Reimbursement Guideline Disclaimer

EmblemHealth has policies in place that reflect billing or claims payment processes unique to our health plans. Current billing and claims payment policies apply to all our products, unless otherwise noted. EmblemHealth will inform you of new policies or changes in policies through updates to the Provider Manual and/or provider news. The information presented in this policy is accurate and current as of the date of this publication.

The information provided in EmblemHealth's policies is intended to serve only as a general reference resource for services described and is not intended to address every aspect of a reimbursement situation. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to: legislative mandates, physician or other provider contracts, the member's benefit coverage documents and/or other reimbursement, medical or drug policies. Finally, this policy may not be implemented the same way on the different electronic claims processing systems used by EmblemHealth due to programming or other constraints; however, EmblemHealth strives to minimize these variations.

EmblemHealth follows coding edits that are based on industry sources, including, but not limited to; CPT guidelines from the American Medical Association, specialty organizations, and CMS including NCCI and MUE. In coding scenarios where there appears to be conflicts between sources, we will apply the edits we determine are appropriate. EmblemHealth uses industry-standard claims editing software products when making decisions about appropriate claim editing practices. Upon request, we will provide an explanation of how EmblemHealth handles specific coding issues. If appropriate coding/billing guidelines or current reimbursement policies are not followed, EmblemHealth may deny the claim and/or recoup claim payment.

Overview

In late 2019, a new Coronavirus was identified as the cause of an outbreak of acute respiratory illness (COVID-19). Since then, an increasing number of COVID-19 cases have been reported in other countries, including the United States, and now Connecticut, Massachusetts, and New York. The purpose of this guidance is to guide providers to the appropriate resources and guidelines relating to COVID-19.

You must use appropriate COVID-19 modifier CS for COVID-19 services related to determining the need for a COVID Test. EmblemHealth will follow CMS' billing guidelines for related services 6/1/2022 until end of PHE.

Guideline

EmblemHealth will cover medically necessary diagnostic tests that are consistent with Centers for Disease Control and Prevention (CDC) guidance related to the COVID-19 at no cost share to members.

EmblemHealth will waive member cost sharing; including copays, coinsurance and deductibles, for COVID-19 diagnostic testing provided at approved locations in accordance with state and federal law and CDC guidelines for all Commercial and Medicare Advantage members.

Criteria to Guide Evaluation and Testing of Patients Under Investigation (PUI) for COVID-19

For the most up to date criteria please visit the CDC website(s) below:

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html>

<https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-coronavirus-3-18-2020.pdf>

Additional Public Health Resources:

Please refer to these links to obtain the most up to date and accurate information COVID-19.

The New York State Department of Health provides public health information and guidance here: <https://www.health.ny.gov/diseases/communicable/coronavirus>, and has implemented a Novel Coronavirus Hotline at 1-888-364-3065.

The Centers for Disease Control and Prevention’s website offers up-to-date information at: <https://www.cdc.gov/coronavirus/2019-ncov/index.html>

Applicable Procedure Codes for COVID-19 Laboratory Testing:

CPT code	Description
U0001	Centers for Disease Control and Prevention (CDC) 2019 Novel Coronavirus Real Time RT-PCR Diagnostic Test Panel
U0002	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19) using any technique, multiple types or subtypes (includes all targets)
U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R. (Effective 3/18/2020)
U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R. (Effective 04/14/2020)
U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date and time of specimen collection. (List separately in addition to either HCPCS code U0003 or U0004) (Effective 1/01/2021)
87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique (Effective 04/14/2020)
87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected (Xpert® Xpress SARSCoV-2/Flu/RSV (SARS-CoV-2 & Flu Targets only), Cepheid)

CPT code	Description
0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected (Xpert® Xpress SARSCoV-2/Flu/RSV (all targets), Cepheid)

Applicable Procedure Codes for COVID-19 Antigen Testing:

CPT code	Description
87426	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) (Effective 06/25/2020)
87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

COVID 19-Antibody Testing:

Effective for dates of service 4/10/2020 (or after); in accordance with CMS and federal guidelines, EmblemHealth will reimburse for COVID-19 Antibody Testing. Antibody blood testing identifies members that have been exposed to the novel coronavirus (SARS-CoV-2) and have developed an immune response. The new codes in the table below are intended for use as the industry standard for accurate reporting and tracking of blood tests performed to specifically detect antibodies associated with the SARS-CoV-2 virus.

Applicable Procedure Codes for COVID-19 Antibody Laboratory Testing:

Must have CLIA Certificate of Compliance or Accreditation for Moderate or High Complexity Testing

CPT code	Description
0224U	<ul style="list-style-type: none"> Antibody, severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed
86328	<ul style="list-style-type: none"> Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) This testing method typically includes a strip with all the critical components for the assay and is appropriate for a point of care platform.

CPT code	Description
86408	<ul style="list-style-type: none"> Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen
86409	<ul style="list-style-type: none"> Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer
86769	<ul style="list-style-type: none"> Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Established for antibody tests using a multiple step method.
86413	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative

Applicable Procedure Codes for COVID-19 Testing -Other Services

CPT code	Description
99211-CS	<ul style="list-style-type: none"> Physician Office specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source
C9803	<ul style="list-style-type: none"> Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source (Outpatient Hospital Facility Only)
99072- Not separately reimbursed	<ul style="list-style-type: none"> Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease

COVID-19 Testing - Specimen Collection from homebound patients and inpatients (not in a hospital):

Effective for dates of service 3/01/2020 (or after); in accordance with CMS guidelines, EmblemHealth will reimburse for transportation and expenses for trained personnel to collect specimens from homebound patients and inpatients (not in a hospital) for purposes of COVID-19 testing.

Note: For payment to be made for sample collection, the method of sample collection must require some training or skill on the part of the laboratory technician and cannot be conducted by the member, the member's caregiver, or facility staff if the facility does not have a laboratory, and therefore, is using an outside laboratory to perform its testing of patients. The technician must personally draw the specimen.

Independent laboratories must use the existing level II HCPCS codes when billing for the travel allowance, that is, the per mile travel allowance as described by HCPCS code P9603 and the flat rate travel allowance as described by HCPCS code P9604.

Note: Paper documentation of miles traveled is not required and laboratories can maintain electronic logs with that information. However, laboratories will need to be able to produce these electronic logs upon request.

Homebound patients as per COVID-19 pandemic applies to those patients:

1. Where a physician has determined that it is medically contraindicated for a member to leave the home because he or she has a confirmed or suspected diagnosis of COVID-19;
or
2. Where a physician has determined that it is medically contraindicated for a member to leave the home because the patient has a condition that may make the patient more susceptible to contracting COVID-19.

Note: A patient who is exercising "self-quarantine" for his or her own safety, would not be considered "homebound" unless it is also medically contraindicated for the patient to leave the home.

Applicable Procedure Codes for COVID-19 Testing Specimen Collection (homebound members):

CPT code	Description
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source (<i>Effective 3/01/2020</i>)
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a SNF (skilled nursing facility) or by a laboratory on behalf of a HHA (Home Health Agency), any specimen source (<i>Effective 3/01/2020</i>)
P9603	Travel allowance, one way, in connection with medically necessary laboratory specimen collection drawn from homebound or nursing homebound patient; miles traveled <ul style="list-style-type: none"> • The per mile travel allowance is to be used in situations where the average trip to patients' homes is <u>longer than 20 miles round trip</u>. • Do not append the LR modifier to P9603, even if you are billing for round trip mileage.
P9604	Travel allowance, one way, in connection with medically necessary laboratory specimen collection drawn from homebound or nursing homebound patient <ul style="list-style-type: none"> • The flat rate travel allowance is to be used in areas where average trips are <u>less than 20 miles round trip</u> • Submitted with modifier LR (laboratory round trip)

Modifier (s) for COVID-19 Services:

Modifier	Description
CR	Disaster related – (Use with 1135 waiver services)
CS	COVID-19 testing related service
DR (CC)	Disaster related – (Use condition code on UB-04 claims)
LR	Laboratory round trip (applies to HCPCS code P9604 only)

ICD-10-CM Official Coding Guidelines — Supplement Coding Encounters Related to COVID-19 Coronavirus Outbreak

FOR ANY SERVICES RELATED TO COVID-19 TESTING PLEASE USE:

During the COVID-19 pandemic, a screening code is generally not appropriate. Do not assign code Z11.52, Encounter for screening for COVID-19. For encounters for COVID-19 testing, including preoperative testing, code as exposure to COVID-19 (guideline I.C.1.g.1.e).

For asymptomatic individuals with actual or suspected exposure to COVID-19, assign code Z20.822, contact with and (suspected) exposure to COVID-19. For symptomatic individuals use Z20.822 as an additional code.

ICD-10-CM Official Coding Guidelines - Supplement Coding Encounters Related to COVID-19 Coronavirus Outbreak

<https://www.cdc.gov/nchs/data/icd/ICD-10cmguidelines-FY2021-COVID-update-January-2021-508.pdf>

For ANY services related to COVID-19 testing, please make sure the following are reported if applicable:

ICD-10	Description
Z20.822	Contact with and (suspected) exposure to COVID-19

Unconfirmed Infections of COVID-19:

In addition to the codes above, for patients presenting with any signs/symptoms (such as fever, etc.) and where a definitive diagnosis has not been established, assign the appropriate code(s) for each of the presenting signs and symptoms such as:

ICD-10	Description	Submitted with:
R05	Cough	Z20.822
R06.02	Shortness of breath	Z20.822
R50.9	Fever, unspecified	Z20.822

Severe acute lower respiratory illness with unconfirmed cases:

ICD-10	Description	Submitted with:
J12.89	Other viral pneumonia	Z20.822
J20.8	Acute bronchitis due to other specified organisms	Z20.822
J80	Acute respiratory distress syndrome (ARDS)	Z20.822
J22	Lower respiratory infection	Z20.822

Confirmed Cases of COVID-19

Effective for dates of service 4/1/2020 or after: (Prior to 4/1/2020 use B97.29 as secondary to respiratory illness)

Severe acute lower respiratory illness with confirmed cases of COVID-19:

Code FIRST U07.1

ICD-10	Description	Submitted with:
U07.1	Pneumonia case confirmed as due to the 2019 novel coronavirus	J12.89
U07.1	Acute bronchitis due to other specified organisms, confirmed as due to the 2019 novel coronavirus	J20.8
U07.1	Acute respiratory distress syndrome (ARDS) confirmed as due to the 2019 novel coronavirus	J80
U07.1	Lower respiratory infection confirmed as due to the 2019 novel coronavirus	J22

For our complete medical necessity guidelines on testing for Coronavirus Disease, please visit our website at www.emblemhealth.com/providers/resources/toolkit/medical-policies

and download our

Testing for Coronavirus Disease 2019 (COVID-19) Medical Policy

Revision History

Date	Revision
09/29/2020	<ul style="list-style-type: none"> New policy with retro effective date of 03/16/2020
11/24/2020	<ul style="list-style-type: none"> Additional CPT/HCPCS codes added
1/21/2021	<ul style="list-style-type: none"> Updated policy to include ICD-10 Code Z20.822 new code effective 1/01/2021 Updated policy to include CPT Code U0005 new code effective 1/01/2021
3/10/2021	<ul style="list-style-type: none"> Removed statement regarding modifier requirement for appropriate cost share to be applied
3/16/2022	<ul style="list-style-type: none"> Updated policy to align with CMS; Modifier CS must be appended to services related to determining the need for COVID test effective 6/01/2022